化合物AZA197 T25125

Product Introduction
Bioactivity


英文名: AZA197

描述: AZA197 (AZA-197)是一种选择性 Cdc42抑制剂。在临床前小鼠异种移植模型中，它通过下调 PAK1活性来抑制原发性结肠癌的生长并延长生存期。

体外活性: In SW620 and HT-29 human colon cancer cells, AZA197(1, 2, 5 and 10 μM; 24 h) demonstrated selectivity for Cdc42 without inhibition of Rac1 or RhoA GTPases from the same family. AZA197 suppressed colon cancer cell proliferation, cell migration and invasion and increased apoptosis associated with down-regulation of the PAK1 and ERK signaling pathways in vitro[1].

体内活性: Systemic AZA197(i.p. injections with 100 μg) treatment reduced tumor growth in vivo and significantly increased mouse survival in SW620 tumor xenografts. Ki-67 staining and tissue TUNEL assays showed that both inhibition of cell proliferation and induction of apoptosis associated with reduced PAK/ERK activation contributed to the AZA197-induced therapeutic effects in vivo[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : Slightly soluble


关键字: AZA197

相关产品: JNJ-7706621 | CDK4/6/1 Inhibitor | BML-259 | SNX7 | Cdc7-IN-7c | PHA-793887 | Ribociclib succinate hydrate | Ergosterol peroxide | Leucettinib-92 | CLK-IN-T3

相关库: Anti-Cancer Compound Library | Bioactive Compounds Library Max | Kinase Inhibitor Library | Inhibitor Library | Anti-Cancer Active Compound Library | Bioactive Compound Library

化合物AZA197 T25125信息由TargetMol中国为您提供，如您想了解更多关于化合物AZA197 T25125报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途